Taysha Gene Therapies to Host Manufacturing Day
July 20 2021 - 7:00AM
Business Wire
Virtual event on Tuesday, July 27, 2021, at
10:00 a.m. ET will highlight the company’s unique three-pillar
approach to manufacturing, its strategic capabilities and other key
considerations
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric,
pivotal-stage gene therapy company focused on developing and
commercializing AAV-based gene therapies for the treatment of
monogenic diseases of the central nervous system (CNS) in both rare
and large patient populations, today announced that it will host a
virtual manufacturing day for analysts and investors. The event
will be webcast live on Tuesday, July 27, 2021, from 10:00 a.m. to
1:00 p.m. ET.
Topics of discussion will include the company’s unique
three-pillar approach to the manufacturing process, its
manufacturing capabilities, the regulatory environment for gene
therapy manufacturing, and the immunology of gene therapy. A
question and answer session will follow each formal
presentation.
The event will feature presentations from Taysha senior
leaders:
- Frederick Porter, Ph.D. Chief Technical Officer, Taysha Gene
Therapies
- Greg Gara Senior Vice President, Manufacturing, Taysha Gene
Therapies
- Suyash Prasad, MBBS, M.Sc., MRCP, MRCPCH, FFPM Chief Medical
Officer and Head of Research and Development, Taysha Gene
Therapies
Registration for this event is available through LifeSci Events.
A live video webcast will be available in the “Events & Media”
section of the Taysha corporate website. An archived version of the
event will be available on the website for 60 days.
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to
eradicate monogenic CNS disease. With a singular focus on
developing curative medicines, we aim to rapidly translate our
treatments from bench to bedside. We have combined our team’s
proven experience in gene therapy drug development and
commercialization with the world-class UT Southwestern Gene Therapy
Program to build an extensive, AAV gene therapy pipeline focused on
both rare and large-market indications. Together, we leverage our
fully integrated platform—an engine for potential new cures—with a
goal of dramatically improving patients’ lives. More information is
available at www.tayshagtx.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “anticipates,” “believes,” “expects,”
“intends,” “projects,” and “future” or similar expressions are
intended to identify forward-looking statements. Forward-looking
statements include statements concerning the potential of our
product candidates, including our preclinical product candidates,
to positively impact quality of life and alter the course of
disease in the patients we seek to treat, our research, development
and regulatory plans for our product candidates, the potential for
these product candidates to receive regulatory approval from the
FDA or equivalent foreign regulatory agencies, and whether, if
approved, these product candidates will be successfully distributed
and marketed, the potential market opportunity for these product
candidates, our corporate growth plans and our plans to establish a
commercial-scale cGMP manufacturing facility to provide
preclinical, clinical and commercial supply. Forward-looking
statements are based on management’s current expectations and are
subject to various risks and uncertainties that could cause actual
results to differ materially and adversely from those expressed or
implied by such forward-looking statements. Accordingly, these
forward-looking statements do not constitute guarantees of future
performance, and you are cautioned not to place undue reliance on
these forward-looking statements. Risks regarding our business are
described in detail in our Securities and Exchange Commission
(“SEC”) filings, including in our Annual Report on Form 10-K for
the full-year ended December 31, 2020, which is available on the
SEC’s website at www.sec.gov. Additional information will be made
available in other filings that we make from time to time with the
SEC. Such risks may be amplified by the impacts of the COVID-19
pandemic. These forward-looking statements speak only as of the
date hereof, and we disclaim any obligation to update these
statements except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210720005181/en/
Company Contact: Kimberly Lee, D.O. SVP, Corporate
Communications and Investor Relations Taysha Gene Therapies
klee@tayshagtx.com
Media Contact: Carolyn Hawley Canale Communications
carolyn.hawley@canalecomm.com
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Apr 2023 to Apr 2024